Dani Brunner
Overview
Explore the profile of Dani Brunner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
645
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang H, Eaton J, Fedolak A, Gunosewoyo H, Onajole O, Brunner D, et al.
Eur J Med Chem
. 2016 Sep;
124:689-697.
PMID: 27639361
We previously reported the cyclopropylpyridine and isoxazolylpyridine ether scaffolds to be versatile building blocks for creating potent α4β2 nicotinic acetylcholine receptor (nAChR) partial agonists with excellent selectivity over the α3β4...
2.
Alexandrov V, Brunner D, Menalled L, Kudwa A, Watson-Johnson J, Mazzella M, et al.
Nat Biotechnol
. 2016 Jul;
34(8):838-44.
PMID: 27376585
Rapid technological advances for the frequent monitoring of health parameters have raised the intriguing possibility that an individual's genotype could be predicted from phenotypic data alone. Here we used a...
3.
Onajole O, Vallerini G, Eaton J, Lukas R, Brunner D, Caldarone B, et al.
ACS Chem Neurosci
. 2016 Apr;
7(6):811-22.
PMID: 27035276
We report the synthesis and biological characterization of novel derivatives of 3-[(1-methyl-2(S)-pyrrolidinyl)methoxy]-5-cyclopropylpyridine (4a-f and 5) as potent and highly selective α4β2-nicotinic acetylcholine receptor (nAChR) full or partial agonists. A systematic...
4.
Oakeshott S, Port R, Cummins-Sutphen J, Berger J, Watson-Johnson J, Ramboz S, et al.
PLoS Curr
. 2015 Dec;
4:e4f972cffe82c0.
PMID: 23925262
Apathy, characterized by generally reduced interest in and likelihood to perform goal-directed actions, is a recognized symptom of Huntington's disease (HD), a devastating neurological disorder caused by a CAG repeat...
5.
Alexandrov V, Brunner D, Hanania T, Leahy E
Eur J Pharmacol
. 2015 Mar;
753:127-34.
PMID: 25744878
Drug testing with traditional behavioral assays constitutes a major bottleneck in the development of novel therapies. PsychoGenics developed three comprehensive highthroughtput systems, SmartCube(®), NeuroCube(®) and PhenoCube(®) systems, to increase the...
6.
Alexandrov V, Brunner D, Hanania T, Leahy E
Eur J Pharmacol
. 2015 Jan;
750:82-9.
PMID: 25592319
Drug testing with traditional behavioral assays constitutes a major bottleneck in the development of novel therapies. PsychoGenics developed three comprehensive high-throughput systems, SmartCube(®), NeuroCube(®) and PhenoCube(®) systems, to increase the...
7.
Yu L, Eaton J, Zhang H, Sabath E, Hanania T, Li G, et al.
Pharmacol Res Perspect
. 2014 Dec;
2(2):e00026.
PMID: 25505580
Preclinical and clinical studies demonstrated that the inhibition of cholinergic supersensitivity through nicotinic antagonists and partial agonists can be used successfully to treat depressed patients, especially those who are poor...
8.
Onajole O, Eaton J, Lukas R, Brunner D, Thiede L, Caldarone B, et al.
ACS Med Chem Lett
. 2014 Nov;
5(11):1196-201.
PMID: 25408831
We report the synthesis and characterization of a series of enantiopure 5-cyclopropane-bearing pyridyldiazabicyclo[3.3.0]octanes that display low nanomolar binding affinities and act as functional agonists at α4β2-nicotinic acetylcholine receptor (nAChR) subtype....
9.
Munafo M, Noble S, Browne W, Brunner D, Button K, Ferreira J, et al.
Nat Biotechnol
. 2014 Sep;
32(9):871-3.
PMID: 25203032
The reliability of scientific research is under scrutiny. A recently convened working group proposes cultural adjustments to incentivize better research practices.
10.
Farrar A, Murphy C, Paterson N, Oakeshott S, He D, Alosio W, et al.
J Huntingtons Dis
. 2014 Jul;
3(2):145-58.
PMID: 25062858
Background: Huntington's disease (HD) is characterized not only by severe motor deficits but also by early cognitive dysfunction that significantly increases the burden of the disease for patients and caregivers....